{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS+Gene+Mutation&page=2",
    "query": {
      "condition": "KRAS Gene Mutation",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS+Gene+Mutation&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T06:47:38.739Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06270082",
      "title": "Study of IK-595 in RAS- or RAF-altered Advanced Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Malignant Melanoma",
        "Ras (Kras or Nras) Gene Mutation",
        "BRAF Gene Mutation",
        "CRAF Gene Mutation",
        "Non-Small Cell Lung Carcinoma",
        "Thyroid Carcinoma",
        "Gliomas, Malignant"
      ],
      "interventions": [
        {
          "name": "IK-595",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ikena Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2023-12-18",
      "completion_date": "2025-09-08",
      "has_results": false,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-05-22T06:47:38.739Z",
      "location_count": 15,
      "location_summary": "Duarte, California • Orange, California • Denver, Colorado + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06270082"
    },
    {
      "nct_id": "NCT04439175",
      "title": "Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Taselisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2016-02-25",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-05-22T06:47:38.739Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04439175"
    },
    {
      "nct_id": "NCT04249843",
      "title": "Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "B-Raf Mutation-Related Tumors"
      ],
      "interventions": [
        {
          "name": "BGB-3245",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MapKure, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2020-02-17",
      "completion_date": "2025-08-04",
      "has_results": false,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-05-22T06:47:38.739Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Boston, Massachusetts • New York, New York + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04249843"
    },
    {
      "nct_id": "NCT05375994",
      "title": "Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "KRAS Activating Mutation",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Malignant Neoplasm of Lung",
        "Malignant Neoplastic Disease"
      ],
      "interventions": [
        {
          "name": "avutometinib (VS-6766) and adagrasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Verastem, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2022-08-01",
      "completion_date": "2026-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-18",
      "last_synced_at": "2026-05-22T06:47:38.739Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05375994"
    },
    {
      "nct_id": "NCT05162443",
      "title": "Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer",
        "Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "adagrasib (MRTX849)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2025-08-26",
      "last_synced_at": "2026-05-22T06:47:38.739Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Santa Rosa, California • Hartford, Connecticut + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05162443"
    },
    {
      "nct_id": "NCT05786924",
      "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Histiocytic Neoplasm",
        "Histiocytosis",
        "BRAF Gene Mutation",
        "BRAF V600E",
        "BRAF V600 Mutation",
        "BRAF Mutation-Related Tumors",
        "BRAF",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Lung Cancer",
        "Recurrent Lung Cancer",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "NSCLC",
        "Solid Tumor",
        "Solid Carcinoma",
        "KRAS G12D",
        "KRAS G12V",
        "KRAS Mutation-Related Tumors",
        "NRAS Gene Mutation",
        "Thyroid Cancer",
        "Thyroid Carcinoma",
        "Colorectal Cancer",
        "Colorectal Carcinoma",
        "Recurrent Histiocytic and Dendritic Cell Neoplasm",
        "Brain Metastases",
        "Recurrent NSCLC",
        "KRAS G13C",
        "Acquired Resistance to KRAS G12C Inhibitor",
        "KRAS G12A",
        "KRAS G12F",
        "KRAS G12R",
        "KRAS G13D"
      ],
      "interventions": [
        {
          "name": "S241656",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX6/FOLFOX7",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Panitumumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institut de Recherches Internationales Servier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 554,
      "start_date": "2023-04-18",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-05-22T06:47:38.739Z",
      "location_count": 10,
      "location_summary": "Gilbert, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05786924"
    },
    {
      "nct_id": "NCT05178888",
      "title": "Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "MRTX849",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2022-01-20",
      "completion_date": "2024-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-02-11",
      "last_synced_at": "2026-05-22T06:47:38.739Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Nashville, Tennessee • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05178888"
    },
    {
      "nct_id": "NCT01298570",
      "title": "Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Regorafenib (BAY 73-4506)",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 181,
      "start_date": "2011-04-07",
      "completion_date": "2020-10-02",
      "has_results": true,
      "last_update_posted_date": "2021-01-06",
      "last_synced_at": "2026-05-22T06:47:38.739Z",
      "location_count": 23,
      "location_summary": "Denver, Colorado • Miami, Florida • Tampa, Florida + 19 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01298570"
    },
    {
      "nct_id": "NCT06162221",
      "title": "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer, NSCLC",
        "KRAS, NRAS, HRAS-mutated NSCLC",
        "KRAS G12C-mutated Solid Tumors, Lung Cancer",
        "Lung Cancer Stage IV, Advanced Solid Tumor, Cancer",
        "RAS G12D-mutated NSCLC"
      ],
      "interventions": [
        {
          "name": "RMC-6291",
          "type": "DRUG"
        },
        {
          "name": "RMC-6236",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "RMC-9805",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 616,
      "start_date": "2024-01-18",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-05-22T06:47:38.739Z",
      "location_count": 26,
      "location_summary": "Gilbert, Arizona • Duarte, California • Irvine, California + 21 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06162221"
    },
    {
      "nct_id": "NCT01333475",
      "title": "MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "MK-2206 + AZD6244",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2011-03",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2015-09-30",
      "last_synced_at": "2026-05-22T06:47:38.739Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01333475"
    }
  ]
}